会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Radioactive transition metal-imido hetero-diphosphine complexes, their preparation and radiopharmaceutical compositions thereof
    • 放射性过渡金属 - 亚氨基杂二膦配合物,它们的制备和放射性药物组合物
    • US07396523B2
    • 2008-07-08
    • US10533988
    • 2003-10-31
    • Francesco TisatoCristina BolzatiMarina PorchiaFiorenzo Refosco
    • Francesco TisatoCristina BolzatiMarina PorchiaFiorenzo Refosco
    • A61K51/00A61M36/14
    • C07F13/005A61K51/0489C07B2200/05C07F9/5004
    • The present invention provides radioactive metal heterocomplexes of formula (I): [(Me═N—R)L1L2]+Z (I), wherein Me, R, L1 L2 and Z− have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium- or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L1, which allows the formation of substitution-inert [(Me═N—R)L1] moieties. Such moieties are fixed in an intermediate [(Me═N—R)Y2L1)]+ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L2 to give the final [(Me═N—R)L1L2]+Z− heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L2 framework or the imido R group.
    • 本发明提供式(I)的放射性金属异复合物:[(Me-NR)L 1 L 2 + Z(I),其中Me,R,L 1 2< 2>和Z - - 具有说明书中指出的含义。 络合物包括三价放射性金属 - 亚氨基,通常是锝或铼 - 酰亚胺基,其通过存在辅助三齿异二膦配体L 1 1强烈稳定,这允许形成取代 -inert [(Me-NR)L 1]部分。 这些部分被固定在含有两个不稳定的,定形的Y(Y)的中间体[(Me-NR)Y 2 L 1 L 1)+ / 配体,其中Y优选为卤化物基团。 后者容易被二齿配体L 2替代,得到最终的[(Me-NR)L 1 L 2 L 2 O 2 + - 异复合物。 本发明的配合物可用于制备放射性药物:事实上,赋予生物寻靶特性的生物活性片段可以在L 2框架或亚氨基R基团上引入。
    • 6. 发明申请
    • RADIOACTIVE TRANSITION METAL-IMIDO HETERO-DIPHOSPHINE COMPLEXES, THEIR PREPARATION AND RADIOPHARMACEUTICAL COMPOSITIONS THEREOF
    • 放射性转移金属 - 咪唑类异双膦酸酯复合物,其制备及放射性能组合物
    • US20080267869A1
    • 2008-10-30
    • US12144370
    • 2008-06-23
    • Francesco TisatoCristina BolzatiMarina PorchiaFiorenzo Refosco
    • Francesco TisatoCristina BolzatiMarina PorchiaFiorenzo Refosco
    • A61K51/04C07F3/00
    • C07F13/005A61K51/0489C07B2200/05C07F9/5004
    • The present invention provides radioactive metal heterocomplexes of formula (I): [(Me=N—R)L1L2]+Z− (I), wherein Me, R, L1 L2 and Z− have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium- or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L1, which allows the formation of substitution-inert [(Me=N—R)L1] moieties. Such moieties are fixed in an intermediate [(Me=N—R)Y2L1)]+ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L2 to give the final [(Me=N—R)L1L2]+ Z−heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L2 framework or the imido R group.
    • 本发明提供了式(I)的放射性金属异复合物:[(Me = NR)L 1 L 2] + Z - (I ),其中Me,R,L 1,L 2,Z 2和Z 2具有说明书中指出的含义。 络合物包括三价放射性金属 - 亚氨基,通常是锝或铼 - 酰亚胺基,其通过存在辅助三齿异二膦配体L 1 1强烈稳定,这允许形成取代 -inert [(Me = NR)L 1]部分。 这些部分固定在含有两个不稳定的,定形的Y(Y)的中间体[(Me = NR)Y 2 L 1 L 1 - 配体,其中Y优选为卤化物基团。 后者容易被二齿配体L 2替代,得到最终的[(Me = NR)L 1 L 2 L 2 + - 异复合物。 本发明的配合物可用于制备放射性药物:事实上,赋予生物寻靶特性的生物活性片段可以在L 2框架或亚氨基R基团上引入。
    • 7. 发明授权
    • Radioactive transition metal-imido hetero-diphosphine complexes, their preparation and radiopharmaceutical compositions thereof
    • 放射性过渡金属 - 亚氨基杂二膦配合物,它们的制备和放射性药物组合物
    • US07771704B2
    • 2010-08-10
    • US12144370
    • 2008-06-23
    • Francesco TisatoCristina BolzatiMarina PorchiaFiorenzo Refosco
    • Francesco TisatoCristina BolzatiMarina PorchiaFiorenzo Refosco
    • A61K51/00A61M36/14
    • C07F13/005A61K51/0489C07B2200/05C07F9/5004
    • The present invention provides radioactive metal heterocomplexes of formula (I): [(Me=N—R)L1L2]+Z− wherein Me, R, L1L2 and Z− have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium-or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L1, which allows the formation of substitution-inert [(Me=N—R)L1] moieties. Such moieties are fixed in an intermediate [(Me=N—R)Y2L1)]+ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L2 to give the final [(Me=N—R)L1L2]+ Z−heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L2 framework or the imido R group.
    • 本发明提供式(I)的放射性金属异复合物:[(Me = N-R)L1L2] + Z-其中Me,R,L1L2和Z-具有说明书中所示的含义。 络合物包括三价放射性金属 - 亚氨基,通常是锝或铼 - 亚胺基,其通过存在辅助三齿异二膦配体L1而稳定,其允许形成取代惰性的[(Me = N- R)L1]部分。 这些部分固定在含有两个不稳定的,定位的Y配体的中间体[(Me = N-R)Y2L1)] +化合物中,其中Y优选为卤素基团。 后者容易被二齿配体L2替代,得到最终的[(Me = N-R)L1L2] + Z-异构复合物。 本发明的复合物可用于制备放射性药物:事实上,赋予生物靶标特性的生物活性片段可以引入到L2骨架或亚胺基R基团上。
    • 9. 发明申请
    • Radioactive transition metal-imido hetero-diphosphine complexes, their preparation and radiopharmaceutical compositions thereof
    • 放射性过渡金属 - 亚氨基杂二膦配合物,它们的制备和放射性药物组合物
    • US20060120957A1
    • 2006-06-08
    • US10533988
    • 2003-10-31
    • Francesco TisatoCristina BolzatiMarina PorchiaFiorenzo Refosco
    • Francesco TisatoCristina BolzatiMarina PorchiaFiorenzo Refosco
    • A61K51/00C07F5/00
    • C07F13/005A61K51/0489C07B2200/05C07F9/5004
    • The present invention provides radioactive metal heterocomplexes of formula (I): [(Me═N—R)L1L2]+Z. (I), wherein Me, R, L1 L2 and Z− have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium- or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L1, which allows the formation of substitution-inert [(Me═N—R)L1] moieties. Such moieties are fixed in an intermediate [(Me═N—R)Y2L1)]+ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L2 to give the final [(Me═N—R)L1L2]+Z−heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L2 framework or the imido R group.
    • 本发明提供式(I)的放射性金属异复合物:[(Me-N-R)L 1 L 2 + Z。 (I),其中Me,R,L 1,L 2和Z 2具有说明书中指出的含义。 络合物包括三价放射性金属 - 亚氨基,通常是锝或铼 - 酰亚胺基,其通过存在辅助三齿异二膦配体L 1 1强烈稳定,这允许形成取代 -inert [(Me-NR)L 1]部分。 这些部分被固定在含有两个不稳定的,定形的Y(Y)的中间体[(Me-NR)Y 2 L 1 L 1)+ / 配体,其中Y优选为卤化物基团。 后者容易被二齿配体L 2替代,得到最终的[(Me-NR)L 1 L 2 L 2 O 2 + - 异复合物。 本发明的配合物可用于制备放射性药物:事实上,赋予生物寻靶特性的生物活性片段可以在L 2框架或亚氨基R基团上引入。